ProQR Therapeutics N.V. Adjustments For Fair Value Gains Losses
ProQR Therapeutics N.V. (PRQR) reported Adjustments For Fair Value Gains Losses of EUR 2.00 thousand for the 3-month period ending 2025-09-30, per its 6-K filed 2025-11-06.
Financial Statements › Income Statement › Other Income
ifrs-full:AdjustmentsForFairValueGainsLosses · last filed 2025-11-06
- ProQR Therapeutics N.V. adjustments for fair value gains losses for the quarter ending 2025-09-30 was 2.00K EUR.
- ProQR Therapeutics N.V. adjustments for fair value gains losses for the quarter ending 2025-06-30 was 104.00K EUR.
- ProQR Therapeutics N.V. adjustments for fair value gains losses for the quarter ending 2025-03-31 was -282.00K EUR, a 514.71% decline year-over-year.
- ProQR Therapeutics N.V. adjustments for fair value gains losses for the quarter ending 2024-09-30 was -139.00K EUR.
| Period end | Adjustments For Fair Value Gains Losses 3 month | Adjustments For Fair Value Gains Losses 6 month | Adjustments For Fair Value Gains Losses 9 month | Adjustments For Fair Value Gains Losses 12 month |
|---|---|---|---|---|
| 2025-09-30 | 2.00K EUR 6-K · filed 2025-11-06 | 106.00K EUR derived: sum of 2 quarters · filed 2025-11-06 | -176.00K EUR 6-K · filed 2025-11-06 | |
| 2025-06-30 | 104.00K EUR 6-K · filed 2025-08-07 | -178.00K EUR 6-K · filed 2025-08-07 | ||
| 2025-03-31 | -282.00K EUR 6-K · filed 2025-05-08 | |||
| 2024-09-30 | -139.00K EUR 6-K · filed 2025-11-06 | -334.00K EUR derived: sum of 2 quarters · filed 2025-11-06 | -266.00K EUR 6-K · filed 2025-11-06 | |
| 2024-06-30 | -195.00K EUR 6-K · filed 2025-08-07 | -127.00K EUR 6-K · filed 2025-08-07 | ||
| 2024-03-31 | 68.00K EUR 6-K · filed 2025-05-08 | |||
| 2023-09-30 | -117.00K EUR 6-K · filed 2024-11-07 | -338.00K EUR derived: sum of 2 quarters · filed 2024-11-07 | -1.01M EUR 6-K · filed 2024-11-07 | |
| 2023-06-30 | -221.00K EUR 6-K · filed 2024-08-08 | -891.00K EUR 6-K · filed 2024-08-08 | ||
| 2023-03-31 | -670.00K EUR 6-K · filed 2024-05-09 | |||
| 2022-09-30 | -5.00K EUR 6-K · filed 2023-11-07 | -67.00K EUR derived: sum of 2 quarters · filed 2023-11-07 | -3.83M EUR 6-K · filed 2023-11-07 | -3.32M EUR derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -62.00K EUR 6-K · filed 2023-08-03 | -3.83M EUR 6-K · filed 2023-08-03 | -3.32M EUR derived: sum of 3 quarters · filed 2023-08-03 | -2.71M EUR derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -3.76M EUR 6-K · filed 2023-05-16 | -3.26M EUR derived: sum of 2 quarters · filed 2023-05-16 | -2.65M EUR derived: sum of 3 quarters · filed 2023-05-16 | -2.61M EUR derived: sum of 4 quarters · filed 2023-05-16 |
| 2021-12-31 | 507.00K EUR 6-K · filed 2022-02-24 | 1.12M EUR derived: sum of 2 quarters · filed 2022-11-09 | 1.15M EUR derived: sum of 3 quarters · filed 2022-11-09 | 1.88M EUR 6-K · filed 2022-02-24 |
| 2021-09-30 | 611.00K EUR 6-K · filed 2022-11-09 | 644.00K EUR derived: sum of 2 quarters · filed 2022-11-09 | 1.37M EUR 6-K · filed 2022-11-09 | 1.15M EUR derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 33.00K EUR 6-K · filed 2022-08-04 | 762.00K EUR 6-K · filed 2022-08-04 | 541.00K EUR derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | 729.00K EUR 6-K · filed 2022-05-05 | 508.00K EUR derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -221.00K EUR 6-K · filed 2022-02-24 | 84.00K EUR 6-K · filed 2022-02-24 |